StreetAlpha.app
Home › Stocks › NBIX

Neurocrine Biosciences Inc (NBIX)

$165.92
▲ +0.30%
LAST CLOSE · NOV 17

Neurocrine Biosciences develops and sells medicines for neurological, psychiatric and endocrine disorders, based in San Diego. It last closed at $165.92 on Nov 17, up 0.30% on the day. NBIX reports earnings on Wed, Feb 10, 2027. The average 12-month price target from 8 analysts is $206.13 (+24.2% from the last close), with a high of $253.00 and a low of $150.00. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (6 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in NBIX, 50% of them bullish and 50% bearish. In the past 30 days there were 3 dark pool prints totaling $2.0M, the largest $727K.

AI Auto Pilots
Is NBIX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$3.7B
+38.0% vs a year ago
Net income
$702.5M
+64.1% vs a year ago
EPS (diluted)
$6.74
+60.9% vs a year ago
Free cash flow
$1.0B
28.1% margin
Valuation
Market cap
$16.8B
101.2M shares
P/E
24.6
Price over 12 month EPS
Price to sales
4.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$641.5M
At Sep 30
Shareholder equity
$3.9B
Buybacks
$158.1M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.1B$1.1BFY2021FY2022: $1.5B$1.5BFY2022FY2023: $1.9B$1.9BFY2023FY2024: $2.4B$2.4BFY2024FY2025: $2.9B$2.9BFY2025

From NBIX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Next report
Feb 10
2027 · Time not announced
Consensus EPS forecast
$2.07
$1.09B revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 8 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
8firms
6 Buy2 Hold0 Sell
Each firm's latest rating on NBIX in the past 90 days
Average 12-month target
$206.13
▲ 24.2% upside

Based on 8 analysts who set a price target on NBIX in the past 90 days. The average target is $206.13, with a high of $253.00 and a low of $150.00, compared with the last close of $165.92.

Low $150.00Avg $206.13High $253.00
Blue marker: last close $165.92
Highest target$253.00
Average target$206.13
Lowest target$150.00
Latest rating changes
GuggenheimTarget raised
Nov 4Buy$207 → $224
RBC CapitalTarget lowered
Nov 3Buy$198 → $190
Canaccord GenuityTarget raised
Nov 3Buy$210 → $220
Piper SandlerTarget raised
Nov 3Buy$210 → $215
BMO CapitalTarget lowered
Oct 12Hold$170 → $150
DateFirmActionRatingPrice target
Nov 4GuggenheimTarget raisedBuy$207 → $224
Nov 3RBC CapitalTarget loweredBuy$198 → $190
Nov 3Canaccord GenuityTarget raisedBuy$210 → $220
Nov 3Piper SandlerTarget raisedBuy$210 → $215
Oct 12BMO CapitalTarget loweredHold$170 → $150
Loading…

Technical Analysis

NBIX · as of the Nov 17 close · updated after every close
Uptrend

The stock is 5% above its 20 day and 10% above its 50 day average. It is 10% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 62). The nearest support is the Pivot at $164.72, and the nearest resistance the Pivot R1 at $167.45.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 3.2%/day
Key levels
$186.1252 week high+12.2%
$169.39Swing high (Jun 10)+2.1%
$167.45Pivot R1+0.9%
$165.92Last close
$164.72Pivot−0.7%
$163.19Pivot S1−1.6%
$158.48Swing low (Aug 6)−4.5%
$157.30100 day average−5.2%
$156.9220 day average−5.4%
$149.17200 day average−10.1%
$148.9950 day average−10.2%
$122.1452 week low−26.4%
Indicators
RSI (14)61.98Strong, overbought above 70Neutral
MACD6.41Above its signal lineBullish
Stochastic73.4Middle of its rangeNeutral
ADX (14)33.3Trending up
Williams %R-28.0Oversold below −80, overbought above −20Neutral
CCI (20)49.1Oversold below −100, overbought above 100Neutral
Rate of change+0.7%Change over 10 sessionsBullish
ATR (14)$5.32Typical daily range, 3.2% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for NBIX

What happened before

See how NBIX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow NBIX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How NBIX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
1
50%
Bearish
1
50%
Date span
Aug 21 – Aug 21
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$2.0M
Largest print
$727K
Loading…

NBIX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●405 buying vs 363 selling
  • ●Held by funds -0.5 pts
  • ▼Funds holding -12
  • ▲Superinvestors: 3 added, 1 cut
  • ▼Put/call 0.03 to 0.05
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding770782−1.5%
In funds' top 1079−22.2%
Held by funds100.0%100.5%−0.5 pts
New / increased101 / 304145 / 320−12.9%
Reduced / sold out256 / 107224 / 65+25.6%
Put/call ratio0.050.03+31.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NBIX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NBIX is in one of them and how their past NBIX trades turned out.

NBIX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NBIX in an article yet. Here's the latest on the wider market.

NBIX Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Aug 13
Who traded NBIX · since 2018
Latest 5 filings of 25
Lisa McClainSell (partial)
$1K – $15KTraded Jun 17, 2025Filed Aug 13, 2025
$1K – $15KTraded Jun 11, 2025Filed Aug 13, 2025
$15K – $50KTraded Nov 19, 2024Filed Dec 16, 2024
$1K – $15KTraded Aug 26, 2024Filed Sep 16, 2024
$1K – $15KTraded Aug 26, 2024Filed Sep 16, 2024
PersonTypeAmountTradedFiledDelay
Lisa McClainR · MISell (partial)$1K – $15KJun 17, 2025Aug 13, 202557 d
Lisa McClainR · MIBuy$1K – $15KJun 11, 2025Aug 13, 202563 d
Michael McCaulR · TXSell$15K – $50KNov 19, 2024Dec 16, 202427 d
Michael McCaulR · TXSell$1K – $15KAug 26, 2024Sep 16, 202421 d
Michael McCaulR · TXSell$1K – $15KAug 26, 2024Sep 16, 202421 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Neurocrine Biosciences

Neurocrine Biosciences is a biopharmaceutical company based in San Diego, California. It discovers, develops and sells medicines for neurological, psychiatric, endocrine and immune disorders. Its main product, INGREZZA, treats tardive dyskinesia and chorea linked to Huntington's disease, and CRENESSITY treats congenital adrenal hyperplasia. In the United States, it sells through specialty pharmacies and distributors, and its sales teams focus on neurology, psychiatry, long-term care and rare diseases.

Headquarters
San Diego, CA
Founded
1992